DCM
OCUL icon

Difesa Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Difesa Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$51.6K – 20
2023
Q2 		$51.6K Buy
+10,000
New +$59.5K 0.14% 31

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Difesa Capital Management's OCUL Position: Q3 2023 in Review

Difesa Capital Management sold out of Ocular Therapeutix (OCUL) in Q3 2023, closing a stake of 10,000 shares — an estimated $51.6K sold.

Difesa Capital Management first reported a position in OCUL in Q2 2023 and held it in 1 quarter. The position peaked at $51.6K in Q2 2023. 113 funds tracked by Wall St. Rank hold OCUL as of Q3 2023.

  • Difesa Capital Management reported no remaining Ocular Therapeutix position as of Q3 2023 after selling out during the quarter.
  • Difesa Capital Management sold 10,000 Ocular Therapeutix shares in Q3 2023, an estimated $51.6K.
  • Difesa Capital Management first reported a position in Ocular Therapeutix in Q2 2023 and held it in 1 quarter.
  • Difesa Capital Management's Ocular Therapeutix position peaked at $51.6K in Q2 2023.
  • 113 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.